Overview

Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

This study compared the pharmacokinetics, pharmacodynamics and the safety of Pegfilgrastim Hospira and Neulasta® following a single dose of 6 mg of each product administered subcutaneously in Treatment Periods 1 and 2, respectively, in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer